← Back to Home

How Can Recurrence Be Prevented After Liver Cancer Resection? Personalized DNA Vaccine Enters Randomized Phase 2 Trial

IMPACT31 plans to enroll 90 patients at high risk of recurrence, comparing personalized DNA immunotherapy with postoperative surveillance. The study will move from early signs of immune responses to a clinical test of whether the treatment can reduce recurrence risk.

By SURL BioNews

Surgery removes visible liver cancer, but the risk of recurrence does not necessarily disappear with it. Whether the immune system can be trained to remember tumor-specific markers and continue recognizing cancer cells after surgery is a question personalized cancer vaccines seek to answer. On October 21, Geneos Therapeutics announced the initiation of IMPACT31, a randomized Phase 2 clinical trial that will test this treatment approach in patients with hepatocellular carcinoma at high risk of recurrence.

The study plans to enroll 90 participants and uses a multicenter, open-label design to compare personalized DNA immunotherapy with active surveillance, meaning ongoing monitoring for recurrence. According to the company announcement, study sites are planned across the United States and the Asia-Pacific region. Trial information from the US National Cancer Institute (NCI) lists participating centers including Johns Hopkins, Mount Sinai, and MD Anderson. The trial identifier is NCT07722741.

The selection of participants highlights how this trial differs from treatment for advanced cancer. According to NCI information, participants must have undergone resection with curative intent, have a high risk of recurrence, and show no evidence of disease on magnetic resonance imaging approximately 28 days after surgery. They must also provide tumor tissue for personalized vaccine development. The study addresses how to reduce the chance of disease returning once tumors are no longer visible on imaging.

Production of GNOS-PV02 begins with sequencing the patient's tumor to identify neoantigens arising from mutations. DNA plasmids then carry the sequences encoding these antigens, with the aim of inducing T-cell responses that recognize the tumor. Although the company announcement describes the trial treatment broadly as personalized immunotherapy, the NCI listing further specifies that the experimental arm includes GNOS-PV02 and INO-9012, a plasmid encoding interleukin-12. The comparison therefore evaluates a treatment combination that includes an immune-stimulating component.

Early evidence supporting this study comes from a Phase 1/2 trial published in *Nature Medicine* in 2024. In that trial, 36 patients with advanced hepatocellular carcinoma received GNOS-PV02, an interleukin-12 plasmid, and the immune checkpoint inhibitor pembrolizumab in combination. The study recorded tumor responses and confirmed neoantigen-specific T-cell responses in some evaluable patients, providing preliminary evidence that this vaccine can mobilize the immune system.

However, the early study was small and lacked a randomized control group, making it difficult to distinguish how much of the treatment effect came from the vaccine and how much from pembrolizumab. Results in patients with advanced disease also cannot be directly applied to postoperative patients. BioPharm International's coverage of the same announcement also noted this limitation. By comparing a postoperative high-risk population with an active surveillance group, IMPACT31 will provide more direct comparative evidence. However, the effects of its open-label design and participant eligibility criteria on the applicability of the results will still need to be considered.

The announcement concerns the initiation of the trial; no efficacy or safety results from IMPACT31 are available yet. For this individually tailored therapy, inducing an immune response is only one hurdle. Whether it can deliver a sustained reduction in recurrence risk after surgery, with benefits sufficient to justify the burden of treatment, is the question this randomized study must now answer.

References

  1. The Manila Times
  2. Geneos Therapeutics
  3. National Cancer Institute
  4. BioPharm International